Back to results
US 11,142,572 B2Granted
Antibodies to human erythroferrone and uses thereof
AssigneeIntrinsic Lifesciences LLC
InventorsMark Westerman, Huiling Han, Vaughn Ostland
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antibodies specific for erythroferrone and assays comprising the antibodies. Also disclosed are methods for using the assays for the diagnosis or monitoring of disease.
Claims20
A method of assessing erythropoiesis in a subject with a disorder associated with erythroferrone (ERFE) or myonectin, comprising subjecting a sample from the subject to an assay comprising:
- contacting the sample with a first antibody to form a first antibody-ERFE complex;
- and then detecting the presence of and/or measuring the amount of a second antibody bound to the first antibody-ERFE complex, wherein the first antibody and the second antibody are not the same and each are independently an ERFE-binding antibody, or an ERFE-binding fragment thereof, the antibodies selected from:
- (a) an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein
- (i) the VH comprises the amino acid sequence of SEQ ID NO:18 and the VL comprises the amino acid sequence of SEQ ID NO:23;
- (ii) the VH comprises the amino acid sequence of SEQ ID NO:28 and the VL comprises the amino acid sequence of SEQ ID NO:33;
- (iii) the VH comprises the amino acid sequence of SEQ ID NO:38 and the VL comprises the amino acid sequence of SEQ ID NO:43;
- (iv) the VH comprises the amino acid sequence of SEQ ID NO:48 and the VL comprises the amino acid sequence of SEQ ID NO:53;
- or
- (v) the VH comprises the amino acid sequence of SEQ ID N0:58 and the VL comprises the amino acid sequence of SEQ ID NO:63,
- or
- (b) an antibody comprising:
- (i) heavy chain complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOs:19-21 and light chain CDRs having the amino acid sequences of SEQ ID NOs:24-26;
- (ii) heavy chain CDRs having the amino acid sequences of SEQ ID NOs:29-31 and light chain CDRs having the amino acid sequences of SEQ ID NOs:34-36;
- (iii) heavy chain CDRs having the amino acid sequences of SEQ ID NOs:39-41 and light chain CDRs having the amino acid sequences of SEQ ID NOs:44-46;
- (iv) heavy chain CDRs having the amino acid sequences of SEQ ID NOs:49-51 and light chain CDRs having the amino acid sequences of SEQ ID NOs:54-56;
- or
- (v) heavy chain CDRs having the amino acid sequences of SEQ ID NOs:59-61 and light chain CDRs having the amino acid sequences of SEQ ID NOs:64-66;
- thus determining the presence, and or the amount, of an ERFE protein in the sample.
15 more elements
A method of assessing erythropoiesis in a subject with a disorder associated with ERFE or myonectin, comprising contacting a sample from a subject with at least one ERFE-binding antibody, or ERFE-binding fragment thereof such that ERFE in the sample is detected and the antibody is selected from:
- (a) an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein
- (i) the VH comprises the amino acid sequence of SEQ ID NO:18 and the VL comprises the amino acid sequence of SEQ ID NO:23;
- (ii) the VH comprises the amino acid sequence of SEQ ID NO:28 and the VL comprises the amino acid sequence of SEQ ID NO:33;
- (iii) the VH comprises the amino acid sequence of SEQ ID NO:38 and the VL comprises the amino acid sequence of SEQ ID NO:43;
- (iv) the VH comprises the amino acid sequence of SEQ ID NO:48 and the VL comprises the amino acid sequence of SEQ ID NO:53;
- or
- (v) the VH comprises the amino acid sequence of SEQ ID N0:58 and the VL comprises the amino acid sequence of SEQ ID NO:63,
- or
- (b) an antibody comprising:
- (i) heavy chain complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOs:19-21 and light chain CDRs having the amino acid sequences of SEQ ID NOs:24-26;
- (ii) heavy chain CDRs having the amino acid sequences of SEQ ID NOs:29-31 and light chain CDRs having the amino acid sequences of SEQ ID NOs:34-36;
- (iii) heavy chain CDRs having the amino acid sequences of SEQ ID NOs:39-41 and light chain CDRs having the amino acid sequences of SEQ ID NOs:44-46;
- (iv) heavy chain CDRs having the amino acid sequences of SEQ ID NOs:49-51 and light chain CDRs having the amino acid sequences of SEQ ID NOs:54-56;
- or
- (v) heavy chain CDRs having the amino acid sequences of SEQ ID NOs:59-61 and light chain CDRs having the amino acid sequences of SEQ ID NOs:64-66.
12 more elements
Dependencies are inferred from the claim text.